MACS® GMP T Cell TransAct™ from Miltenyi Biotec

BERGISCH GLADBACH, April 20, 2017 – MACS® GMP T Cell TransAct™ is a ready-to-use reagent for efficient in vitro activation and expansion of human T cells. Also available in research grade.  

BERGISCH GLADBACH, April 20, 2017 – MACS® GMP T Cell TransAct™ is a ready-to-use reagent for efficient in vitro activation and expansion of human T cells. Also available in research grade.  

Cell activation is a prerequisite for the successful genetic engineering of T cells. MACS GMP T Cell TransAct from Miltenyi Biotec – with its unique features – enables in vitro stimulation, activation, and expansion of human T cells from hematological cell populations (e.g. PBMCs). Polyclonal T cell expansion can be used in numerous applications including cellular therapy or whenever T cells are activated to improve gene modification.
Benefits of MACS GMP T Cell TransAct are:

Innovative format: A colloidal polymeric nanomatrix conjugated to humanized, recombinant CD3 and CD28 agonists.

Ease of use: Effective activation for a large range of cell densities.

Convenience: Excess reagent is simply washed off.

Safety: Biodegradable, ready to use and compatible with the automated, functionally-closed CliniMACS Prodigy® System.


Due to the nanoscale structure of MACS GMP T Cell TransAct, the reagent can be sterile filtered. Excess reagent can be removed by simple supernatant replacement. The reagent is finely tuned to work best in combination with TexMACS™ GMP Medium. MACS GMP T Cell TransAct is suitable for the use in automated cell manufacturing systems, such as the CliniMACS Prodigy.

In the US, MACS GMP T Cell TransAct is for use under an approved IND.

For further information see miltenyibiotec.com/transact


Meet us at one of the following events: 
May 3–6, 2017          ISCT 2017, London, UK
May 12–16, 2017     AAI 2017, Washington, DC, USA
May 22–23, 2017     Cell & Gene Exchange 2017, Washington, DC, USA


About Miltenyi Biotec 
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,700 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health. For more information please visit www.miltenyibiotec.com

 

Miltenyi Biotec Media Contact

Dr. Anja Kohmann
Communications Manager  
anja.kohmann@miltenyibiotec.de  

 


Publication free of charge – Specimen copy requested.

Download media release (PDF)